JP6890340B6 - グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 - Google Patents
グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 Download PDFInfo
- Publication number
- JP6890340B6 JP6890340B6 JP2018511277A JP2018511277A JP6890340B6 JP 6890340 B6 JP6890340 B6 JP 6890340B6 JP 2018511277 A JP2018511277 A JP 2018511277A JP 2018511277 A JP2018511277 A JP 2018511277A JP 6890340 B6 JP6890340 B6 JP 6890340B6
- Authority
- JP
- Japan
- Prior art keywords
- body weight
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214449P | 2015-09-04 | 2015-09-04 | |
| US62/214,449 | 2015-09-04 | ||
| US201562259061P | 2015-11-24 | 2015-11-24 | |
| US62/259,061 | 2015-11-24 | ||
| PCT/US2016/050183 WO2017040986A1 (en) | 2015-09-04 | 2016-09-02 | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018528210A JP2018528210A (ja) | 2018-09-27 |
| JP2018528210A5 JP2018528210A5 (cg-RX-API-DMAC7.html) | 2019-11-28 |
| JP6890340B2 JP6890340B2 (ja) | 2021-06-18 |
| JP6890340B6 true JP6890340B6 (ja) | 2021-07-14 |
Family
ID=58188491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511277A Active JP6890340B6 (ja) | 2015-09-04 | 2016-09-02 | グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10765737B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3344279B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6890340B6 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108348582B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016318097B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2999747A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017040986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7005638B2 (ja) | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | グルカゴン受容体結合タンパク質及びその使用方法 |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン18抗体及びそれらの使用の方法 |
| CN118393150B (zh) * | 2024-06-27 | 2024-09-13 | 潍坊市润生畜禽良种有限公司 | 一种优化gcgr卵黄抗体制备的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030103983A1 (en) | 2002-05-09 | 2003-06-05 | Pressler Milton Lethan | Ace inhibitor-vasopressin antagonist combinations |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
-
2016
- 2016-09-02 CA CA2999747A patent/CA2999747A1/en active Pending
- 2016-09-02 WO PCT/US2016/050183 patent/WO2017040986A1/en not_active Ceased
- 2016-09-02 AU AU2016318097A patent/AU2016318097B2/en not_active Ceased
- 2016-09-02 EP EP16843103.9A patent/EP3344279B1/en active Active
- 2016-09-02 JP JP2018511277A patent/JP6890340B6/ja active Active
- 2016-09-02 CN CN201680061804.XA patent/CN108348582B/zh active Active
- 2016-09-02 US US15/757,352 patent/US10765737B2/en active Active
-
2020
- 2020-07-28 US US16/941,290 patent/US11446376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200353079A1 (en) | 2020-11-12 |
| US11446376B2 (en) | 2022-09-20 |
| CN108348582B (zh) | 2023-04-14 |
| JP2018528210A (ja) | 2018-09-27 |
| AU2016318097B2 (en) | 2023-04-20 |
| AU2016318097A1 (en) | 2018-04-12 |
| CA2999747A1 (en) | 2017-03-09 |
| WO2017040986A1 (en) | 2017-03-09 |
| EP3344279A1 (en) | 2018-07-11 |
| US20180256713A1 (en) | 2018-09-13 |
| US10765737B2 (en) | 2020-09-08 |
| CN108348582A (zh) | 2018-07-31 |
| JP6890340B2 (ja) | 2021-06-18 |
| EP3344279A4 (en) | 2019-03-27 |
| EP3344279B1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12534503B2 (en) | Mutant fibroblast growth factor 21 (FGF21) polypeptides | |
| US11446376B2 (en) | Methods for treating heart failure using glucagon receptor antagonistic antibodies | |
| JP6861641B2 (ja) | グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法 | |
| US20230075314A1 (en) | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF | |
| KR102442984B1 (ko) | 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법 | |
| KR102701695B1 (ko) | 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 | |
| CN102171240A (zh) | 治疗炎症的方法 | |
| KR20210132232A (ko) | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 | |
| MXPA05012497A (es) | Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars). | |
| TW201113036A (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
| UA129672C2 (uk) | Антитіло до trem-1 та його застосування | |
| WO2012135868A2 (en) | Compositions and methods for the treatment and prevention of cardiac ischemic injury | |
| KR20220131223A (ko) | Dkk-1 억제제를 사용하여 암을 치료하는 방법 | |
| WO2011116245A2 (en) | Methods of treating inflammation | |
| CN115279393A (zh) | 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190830 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201201 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210420 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210518 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6890340 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |